Working Up Group 4 Equivocal HER2 Samples Tested by Fluorescence in Situ Hybridization in a Reference Laboratory Setting: Past, Present, and Future

J Clin Oncol. 2020 Jan 10;38(2):175-176. doi: 10.1200/JCO.19.02482. Epub 2019 Nov 26.

Authors

Katherine B Geiersbach¹, Reid G Meyer¹, Daniel R Sill¹, Taofic Mounajjed¹, Beiyun Chen¹, William R Sukov¹, Robert B Jenkins¹

Affiliation

¹ Katherine B. Geiersbach, MD; Reid G. Meyer; Daniel R. Sill; Taofic Mounajjed, MD; Beiyun Chen, MD, PhD; William R. Sukov, MD; and Robert B. Jenkins, MD, PhD, Mayo Clinic School of Medicine, Rochester, MN.

PMID: 31770062
DOI: 10.1200/JCO.19.02482

No abstract available

Publication types

Letter

MeSH terms

Biomarkers, Tumor / analysis
Biomarkers, Tumor / genetics
Breast Neoplasms / enzymology*
Breast Neoplasms / genetics
Female
Guidelines as Topic
Humans
In Situ Hybridization, Fluorescence / methods*
In Situ Hybridization, Fluorescence / standards*
In Situ Hybridization, Fluorescence / trends
Receptor, ErbB-2 / analysis
Receptor, ErbB-2 / biosynthesis
Receptor, ErbB-2 / genetics*
Reference Standards

Substances

Biomarkers, Tumor
ERBB2 protein, human
Receptor, ErbB-2